XM无法为美国居民提供服务。
S
S

Sanofi


市场新闻

European shares end week in the red as earnings disappoint

UPDATE 2-European shares end week in the red as earnings disappoint Mercedes car earnings plunge as China shuns luxury Electrolux slides on US woes, Chinese competition Signify shares soar as largely in-line Q3 provides relief Updated at 1603 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 25 (Reuters) - Europe's main stock index closed Friday's choppy session flat and notched weekly losses , as a handful of weak corporate earnings from auto-related companies such as Mercedes-Benz a
E
R
S
V
F

Sanofi shares seen up after Q3 beat

BUZZ-Sanofi shares seen up after Q3 beat ** Shares in Sanofi SASY.PA are seen up 1%-3.5% after the French pharma giant published Q3 results above expectations ** The group reported net sales for the quarter 6% above consensus at 13.44 billion euros ($14.53 billion), while business net income beat analyst expectations by 15% to 3.59 billion euros ** J.P.
S

Sanofi profit growth beats market view on early start of vaccine sales

REFILE-UPDATE 1-Sanofi profit growth beats market view on early start of vaccine sales Refiles with with name of analyst firm in paragraph 7 By Ludwig Burger Oct 25 (Reuters) - French drug maker Sanofi SASY.PA on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.
S

MARKETS ENTER THE EVENT STORM

LIVE MARKETS-MARKETS ENTER THE EYE OF RISK-EVENT STORM Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com MARKETS ENTER THE EYE OF RISK-EVENT STORM Yields are mercifully lower as the week draws to a close, removing some of the angst that has weighed on equities and allowing the beaten-down yen and euro to regain some composure against the dollar .
A
A
G
M
S
T
J
U
E
F
U
G

Sanofi Q3 Business Operating Income Eur 4,607 Mln, Above Consensus

BRIEF-Sanofi Q3 Business Operating Income Eur 4,607 Mln, Above Consensus Oct 25 (Reuters) - Sanofi SA SASY.PA : Q3 NET SALES EUR 13,438 MLN VS EUR 12,672 MLN IN VARA CONSENSUS Q3 BUSINESS EPS EUR 2.86 MLN VS EUR 2.49 MLN IN VARA CONSENSUS Q3 FREE CASH FLOW EUR 3,327 MLN, UP 79.5% YOY Q3 GROSS PROFIT EUR 10,074 MLN VS EUR 9,444 MLN IN VARA CONSENSUS
S

Sanofi CFO says won't be affected by Novo's Catalent deal

Sanofi CFO says won't be affected by Novo's Catalent deal FRANKFURT, Oct 25 (Reuters) - Sanofi's SASY.PA finance chief on Friday said the company won't be affected by Novo Nordisk's NOVOb.CO controlling shareholder's decision to acquire contract drug manufacturer Catalent CTLT.N , adding the deal made sense for its rival. "They desperately need capacity so it makes sense for them," Sanofi CFO Francois-Xavier Roger said in a media call after the release of third-quarter results .
S

Sanofi Q3 earnings beat market view, boosted by vaccine sales

Sanofi Q3 earnings beat market view, boosted by vaccine sales Oct 25 (Reuters) - French drug maker Sanofi SASY.PA on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines. Quarterly business operating income, excluding one-off items, rose by 14.4% to 4.6 billion euros ($5.0 billion), surpassing the average analyst estimate of 4 billion euros in a poll posted on the company's website.
S

Markets enter the eye of risk-event storm

MORNING BID EUROPE-Markets enter the eye of risk-event storm A look at the day ahead in European and global markets from Kevin Buckland Yields are mercifully lower as the week draws to a close, removing some of the angst that has weighed on equities and allowing the beaten-down yen and euro to regain some composure against the dollar . But this relative calm feels like the eye of the storm as risk events swirl on the horizon next week: mega-cap earnings from five of the "Magnificent 7"; a highly
A
A
E
M
S
T
U
J
U
U
U

Dealmakers expect bigger European private equity buyouts and more of them

ANALYSIS- Dealmakers expect bigger European private equity buyouts and more of them Number of $5bn plus deals more than doubled in year to date Uninvested cash has piled up Private equity investors press for returns through asset sales By Amy-Jo Crowley, Andres Gonzalez, Mathieu Rosemain and Anousha Sakoui LONDON, Oct 22 (Reuters) - Buyout fund CD&R's keenly awaited 16 billion euro ($17.36 billion) deal to take control of Sanofi's consumer health unit, could herald an upsurge in big private equi
S

British Business - Oct. 22

PRESS DIGEST-British Business - Oct. 22 Oct 21 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - British engineering company Ricardo RCDO.L said it is divesting its defence business as part of a five-year strategic shift to become an "engineering consultancy in environmental and energy transition".
M
O
P
S
V
V

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Secureworks, Atlantic Union Bankshares, Catalent, Viad Corp Updates: EQT AB, DNB, CITIC Ltd Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Cybersecurity firm Sophos, which is backed by private equity firm Thoma Bravo, said it will acquire Secureworks SCWX.O for $859 million in an all-cash deal to strengthen its cybersecurity offering for small, mid and enterprise customers.
M
S
U
D

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** China's state-owned CITIC Ltd 0267.HK has agreed to sell its 19.23% stake in Fast Food Holdings, the company behind McDonald's China and Hong Kong operations, to Trustar Fast Food Holdings for $430.3 million.
M
S
U

STOXX 600 finishes lower ahead of key earnings reports

UPDATE 2-STOXX 600 finishes lower ahead of key earnings reports For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Forvia jumps on supply deal with China's BYD, Xiaomi SAP, bank earnings in focus this week Updated at 1600 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 21 (Reuters) - European shares ended Monday's choppy session in the red ahead of a series of marquee corporate earnings, although stabilising oil prices buoyed
B
D
L
M
S
S
E
F
I
S
G

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 21 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. FORVIA FRVIA.PA The company on Monday posted third-quarter sales , flagging some optimism linked to its operation in China. SANOFI SASY.PA The French company said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S.
S
F
N
U

Sanofi in exclusive talks with CD&R over sale of $17 bln Opella

UPDATE 3-Sanofi in exclusive talks with CD&R over sale of $17 bln Opella Opella has been valued at around 16 bln euros, Sanofi says Paris given guarantees on jobs and production, sources say Sanofi increases 2024 earnings per share guidance Adds state to take a seat on board in paragraph 2, shares in 9 By Dominique Patton PARIS, Oct 21 (Reuters) - French drugmaker Sanofi SASY.PA said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella t
S

Sanofi enters exclusive talks with CD&R for Opella sale

Sanofi enters exclusive talks with CD&R for Opella sale PARIS, Oct 21 (Reuters) - Sanofi SASY.PA said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.38 billion), or 14 times EBITDA in 2024, and French public investment bank Bpifrance is expected to take
S

Financial Times - Oct 21

PRESS DIGEST- Financial Times - Oct 21 Oct 21 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Public to be asked for suggestions on how to fix NHS - French state takes stake in Sanofi unit to smooth 15.5 billion euro ($16.84 billion) deal Overview UK health secretary Wes Streeting will on Monday launch a "national conversation" about the future of the National Health Service, which he
S

REUTERS NEWS SCHEDULE AT 6 a.m SGT / 6 p.m. ET

REUTERS NEWS SCHEDULE AT 6 a.m SGT / 6 p.m. ET Here are the top stories and upcoming coverage plans for Reuters text service as of 6 a.m SGT / 6 p.m. ET. For a full schedule of news and events, go to our editorial calendar on Reuters Connect . TOP STORIES GLOBAL ISRAEL-PALESTINIANS/ Lebanese flee as Israel warns of strikes on Hezbollah financial arm BEIRUT/CAIRO (Reuters)- Hundreds of Beirut residents fled their homes late on Sunday after Israel said it was preparing attacks on sites linked to t
B
B
M
N
S
T

Sanofi reaches deal on terms of sale of consumer health arm, say French government sources

UPDATE 1-Sanofi reaches deal on terms of sale of consumer health arm, say French government sources Adds details, background PARIS, Oct 20 (Reuters) - Sanofi SASY.PA on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French government sources said on Sunday.
S

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI PARIS, Oct 20 (Reuters) - France will take a stake in Sanofi SASY.PA 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France's most-sold painkillers, Doliprane.
S



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明